IC
OBIO icon

Ikarian Capital’s Orchestra BioMed OBIO Stock Holding History

Ikarian Capital’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-197,173
Closed -$1.95M – 223
2021
Q3 		$1.95M Sell
197,173
-2,827
-1% -$27.9K 0.14% 127
2021
Q2 		$2.04M Hold
200,000
– – 0.16% 126
2021
Q1 		$2.25M Buy
+200,000
New +$2.44M 0.08% 194

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital's OBIO Position: Q4 2021 in Review

Ikarian Capital sold out of Orchestra BioMed (OBIO) in Q4 2021, closing a stake of 197,173 shares — an estimated $1.95M sold.

Ikarian Capital first reported a position in OBIO in Q1 2021 and held it in 3 quarters. The position peaked at $2.25M in Q1 2021. 53 funds tracked by Wall St. Rank hold OBIO as of Q4 2021.

  • Ikarian Capital reported no remaining Orchestra BioMed position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 197,173 Orchestra BioMed shares in Q4 2021, an estimated $1.95M.
  • Ikarian Capital first reported a position in Orchestra BioMed in Q1 2021 and held it in 3 quarters.
  • Ikarian Capital's Orchestra BioMed position peaked at $2.25M in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.